Prognostic factors in patients with relapsed or refractory diffuse large B-cell lymphoma who underwent autologous stem-cell transplantation-Reference-Cited by-同舟云学术

Prognostic factors in patients with relapsed or refractory diffuse large B-cell lymphoma who underwent autologous stem-cell transplantation

Published:2016 Issue:3 Volume:5 Page:93-101
ISSN:2186-5612
Container-title:Journal of Hematopoietic Cell Transplantation
language:en
Short-container-title:Journal of Hematopoietic Cell Transplantation

Author:

Ohmoto Akihiro¹²,Fuji Shigeo¹,Miyagi-Maeshima Akiko²,Tajima Kinuko¹,Tanaka Takashi¹,Ito Reiko¹,Inoue Yoshitaka¹,Okinaka Keiji¹,Kurosawa Saiko¹,Inamoto Yoshihiro¹,Yamashita Takuya¹,Taniguchi Hirokazu²,Makita Shinichi³,Kitahara Hideaki³,Munakata Wataru³,Suzuki Tatsuya³,Maruyama Dai³,Kobayashi Yukio³,Tanosaki Ryuji⁴,Tobinai Kensei³,Fukuda Takahiro¹,Kim Sung-Won¹

Affiliation:

1. Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital

2. Department of Pathology and Clinical Laboratory, National Cancer Center Hospital

3. Department of Hematology, National Cancer Center Hospital

4. Department of Blood Transfusion and Cellular Therapy, National Cancer Center Hospital

Publisher

The Japan Society for Hematopoietic Stem Cell Transplantation

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/hct/5/3/5_93/_pdf

Reference28 articles.

1. 1. Nogai H, Dörken B, Lenz G. Pathogenesis of non-Hodgkin’s lymphoma. J Clin Oncol. 2011; 29: 1803-1811.

2. 2. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7: 379-391.

3. 3. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007; 109: 1857-1861.

4. 4. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995; 333: 1540-1545.

5. 5. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1987; 316: 1493-1498.